Table 5.
Antihypertensive agents used in the completed phase III ramucirumab clinical trials
| Patients receiving concurrent antihypertensive therapiesa,b |
||
|---|---|---|
| RAM, n (%) | Control, n (%) | |
| REGARD | 101 (42.8) | 46 (40.0) |
| RAINBOW | 180 (55.0) | 124 (37.7) |
| REVEL | 159 (25.4) | 109 (17.6) |
| RAISE | 329 (62.2) | 286 (54.2) |
| REACH | 223 (80.5) | 201 (72.8) |
| ROSE | 379 (50.4) | 167 (43.7) |
Patient is only counted once for each category.
a
Concurrent antihypertensive therapy includes any antihypertensive therapy received between treatment start date and 30 days after treatment end, including therapies that may have started before treatment start date.
b
Antihypertensive therapies included diuretics, peripheral vasodilators, beta-blocking agents, calcium channel antagonists, renin angiotensin agents, and other antihypertensive therapy.
RAM, ramucirumab.